Anti-PKN3 siRNA Atu027

Preferred Label : Anti-PKN3 siRNA Atu027;

NCIt related terms : ATU-027;

NCIt definition : A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and fusiogenic lipids with potential antineoplastic activity. Upon administration, catiogenic and fusiogenic lipids promote anti-PKN3 siRNA Atu02 uptake by tumor cells; the siRNAs moieties are subsequently released once inside the cell. The siRNAs bind to PKN3 mRNAs, which may result in the inhibition of translation and expression of the PKN3 protein and, so, growth inhibition of tumor cells that overexpress PKN3. The protein kinase C-related molecule PKN3, downstream in the phosphoinositide-3-kinase (PI3K) signaling pathway, is upregulated in many tumor cells and plays an important role in invasive cell growth and metastasis.;

UNII : IFJ2SAK127;

CAS number : 1415935-22-6;

Molecule name : Atu027;

Details

Origin ID

C84847;

UMLS CUI

C2827525;

Currated CISMeF NLP mapping
- Atu027 [MeSH Supplementary Concept]
- Atu027 [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Atu027 [MeSH Supplementary Concept]
- Atu027 [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients